Skip to content

The Clinical Study for Qingfei Huatan Granule to Reduce the Course of Acute Exacerbation of COPD

Clinical Study for Qingfei Huatan Granule to Reduce the Course of Acute Exacerbation of COPD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026576
Enrollment
Unknown
Registered
2019-10-14
Start date
2019-10-14
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease,

Interventions

Sponsors

The First Affiliated Hospital of Anhui University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. A confirmed diagnosis of AECOPD; 2. Syndrome of phlegm-heat obstructing lung; 3. Aged between 40 and 80 years; 4. Voluntary treatment, with the informed consent signed.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women; 2. Complicated with cardio-cerebrovascular diseases (malignant arrhythmia, unstable hemodynamics, acute myocardial infarction, NYHA Class III or IV,cerebral apoplexy, cerebral hemorrhage, etc); 3. Complicated with bronchiectasis, bronchial asthma, tuberculosis, bronchiolitis obliterans, diffuse panbronchiolitis, pulmonary embolism pneumothorax and pleural effusion, etc; 4. Complicated with respiratory failure, need endotracheal intubation and ventilator breathing to assist breathing; 5. Complicated with serious liver and renal diseases(Serious liver disease refers to cirrhosis, portal hypertension and varices bleeding,severe kidney disease, including dialysis, kidney transplantation); 6. Combination of tumor or neuromuscular disease affecting the respiratory movement function; 7. Long-term bedridden patients; 8. Congenital or acquired immunodeficiency; 9. Delirious, dementia, and all kinds of psychiatric patients; 10. Patients with oral corticosteroids within 1 mounth before enrollment; 11. Participating in other trials within 1 mounth before enrollment or allergic to the used medicine.

Design outcomes

Primary

MeasureTime frame
course of disease;

Secondary

MeasureTime frame
antibiotic use time;The clinical symptoms and physical signs;TCM syndrome grade;The category and use time of the application of antiasthmatic during the period of COPD exacerbations;inflammatory indicators;Dyspnea;Quality of life evaluation;lung function;

Countries

China

Contacts

Public ContactZhu Huizhi

The First Affiliated Hospital of Anhui University of Chinese Medicine

huizhizhu87@163.com+86 13339297671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026